September 2006 in “Aktuelle Urologie” Combination drug therapies are more effective for high-risk BPS patients but have more side effects and costs.
5 citations
,
January 2001 in “Advances in protein chemistry” 5α-reductase inhibitors help treat disorders caused by DHT and have potential for future therapies.
29 citations
,
January 1996 in “Journal of Pharmaceutical Sciences” Finasteride poorly inhibits type 1 5AR, affecting its effectiveness.
January 2018 in “Surgical and Cosmetic Dermatology” 5-alpha reductase inhibitors like finasteride and dutasteride are effective for treating enlarged prostate and male pattern hair loss.
26 citations
,
October 2011 in “International Journal of Biological Macromolecules” Some newly made compounds are promising for treating enlarged prostate, hair loss, viruses, and prostate cancer, and might be better than current drugs.
Dutasteride is more effective than finasteride for treating BPH without extra safety risks.
January 2005 in “Urologia Journal” 5αR inhibitors help slow early prostate cancer cell growth, suggesting combined treatments are needed.
18 citations
,
October 2010 in “Bioorganic & Medicinal Chemistry Letters” New hybrid compound found to effectively prevent hair loss.
April 2019 in “The Journal of urology/The journal of urology” Prescriptions for 5-alpha reductase inhibitors dropped significantly after the FDA's safety warning, especially for men with benign prostatic hyperplasia.
6 citations
,
August 2013 in “한국응용생명화학회지” Certain natural compounds can block an enzyme linked to prostate enlargement and hair loss, showing potential for new treatments.
June 2026 in “Pharmaceuticals” 5α-Reductase inhibitors, like finasteride, can cause serious, persistent side effects not always listed in official drug information.
September 2022 in “PubMed” Entadfi, a mix of finasteride and tadalafil, is used for BPH.
12 citations
,
April 2020 in “Medical hypotheses” Men on 5-alpha-reductase inhibitors might have worse COVID-19 outcomes.
January 2026 in “Andrology” PRP injections are safe but don't significantly improve Peyronie's Disease.
6 citations
,
July 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Finasteride and dutasteride have limited use in feminising therapy and are not recommended for routine use.
December 2025 in “OPAL (Open@LaTrobe) (La Trobe University)” A new combination of tadalafil and finasteride improves drug performance and stability.
December 2018 in “Actas urológicas españolas” 5-alpha reductase inhibitors may have additional effects on cancer, mental health, heart health, and hormone levels beyond treating prostate enlargement.
April 2017 in “Austin Journal of Cancer and Clinical Research” 5α-reductase inhibitors like Finasteride and Dutasteride may help manage prostate cancer by blocking testosterone conversion.
March 2005 in “Current Prostate Reports”
3 citations
,
January 2001 in “Cambridge University Press eBooks” Finasteride effectively treats hair loss and enlarged prostate in men, with mild side effects.
March 2014 in “The Journal of Urology” Long-term treatment with finasteride or combined therapy worsens sexual function in men with urinary issues.
November 2024 in “Journal of Family Medicine and Primary Care” 5 alpha reductase inhibitors can cause sexual, cognitive, and muscle side effects, and may slightly increase aggressive cancer risk.
January 2026 in “Yonsei Medical Journal” Finasteride and dutasteride have little effect on Type 2 Diabetes risk.
29 citations
,
September 2014 in “Current Opinion in Endocrinology, Diabetes and Obesity” Finasteride and dutasteride effectively treat hair loss in men and women, but may cause side effects like low libido and depression.
18 citations
,
November 2012 in “Current opinion in urology” Finasteride and dutasteride are equally effective and safe for treating benign prostatic hyperplasia.
20 citations
,
June 2007 in “Recent Patents on Endocrine, Metabolic & Immune Drug Discovery” Certain inhibitors can potentially treat prostate cancer and other hormone-dependent conditions by controlling sex hormone levels in cells.
6 citations
,
August 2021 in “Clinical Epidemiology” Men using 5-alpha reductase inhibitors for prostate issues may have a slightly higher risk of blood clots.
July 2020 in “Vestnik urologii” The cause of post-finasteride syndrome is unclear and needs more research.
May 2022 in “Endocrine Abstracts” Finasteride may cause sexual dysfunction by reducing epinephrine levels.
The document suggests that drugs for prostate issues might cause lasting sexual, mental, and physical health problems due to blood vessel damage in the penis.